Heijerman
HGM
et al; VX17-445-103 Trial Group. Efficacy and safety of the elexacaftor plus tezacaftor plus
ivacaftor combination regimen in people with cystic fibrosis homozygous for the
F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019 Nov 23;394(10212):1940–8.
[PubMed: 31679946]